Relapse in leprosy and type II reaction in a patient treated with multidrug therapy (MDT)

Montaño Padilla, Gina Sofía; Lancheros González, Paula Catalina; Celis, Luis Gustavo

dc.contributor	Al Doctor Gerzaín Rodríguez Toro, la Doctora Edna Ruth Padilla, la Doctora Elga Johanna Vargas	es-ES
dc.creator	Montaño Padilla, Gina Sofía
dc.creator	Lancheros González, Paula Catalina
dc.creator	Celis, Luis Gustavo
dc.date	2014-06-15
dc.date.accessioned	2019-11-08T21:24:34Z
dc.date.available	2019-11-08T21:24:34Z
dc.identifier	http://hemeroteca.unad.edu.co/index.php/nova/article/view/1000
dc.identifier	10.22490/24629448.1000
dc.identifier.uri	https://repository.unad.edu.co/handle/10596/29918
dc.description	Leprosy is a chronic infectious disease endemic to African, Asian, Latin America and South Pacific countries. It is caused by Mycobacterium leprae that manifests itself as varied as areas of hypo or anesthesia, macules hypochromic, with or without neura thickening. On some occasions, after having completed the course of therapy recommended by the World Health Organization, it can recur, showing new clinical lesions or increasing the bacillary index. These features can be confused with erythema nodosum leprosum, characterized by an antigen-antibody reaction that secures a complement through which the immune system combats antigen cells. This text describes a case of recurrence of lepromatous leprosy and lesions compatible with erythema nodosum leprosum after it has been treated with combination chemotherapy.	en-US
dc.description	La lepra es una enfermedad infecciosa crónica propia de países de África, Asia, Oceanía y América Latina. Es causada por el Mycobacterium leprae que se manifiesta de forma variada como zonas de hipo o anestesia, máculas hipocrómicas, con o sin engrosamiento neural. En algunas ocasiones, después de haber completado el ciclo terapéutico recomendado por la Organización Mundial de la Salud, puede presentar recidivas, apareciendo nuevas lesiones clínicas o aumentando el índice bacilar. Esta características pueden confundirse con el eritema nodoso leproso, caracterizado por ser una reacción antígeno-anticuerpo que fija complemento mediante la cual el sistema inmune combate antígenos bacilares. En este texto se describe un caso de recidiva de lepra lepromatosa y lesiones compatibles con eritema nodoso leproso después de haber sido tratado con poliquimioterapia.	es-ES
dc.format	application/pdf
dc.language	spa
dc.publisher	Universidad Colegio Mayor de Cundinamarca	es-ES
dc.relation	http://hemeroteca.unad.edu.co/index.php/nova/article/view/1000/986
dc.relation	/ref/Rodríguez G, Pinto R. La Lepra. Imágenes y Conceptos. Medellín. Universidad de la Sabana, Universidad de Antioquia; 2007.
dc.relation	/ref/Diana N.J. Lockwood & María Da Graca Cunha. Developing new MDT regimens for MB patients; Time to test ROM 12 month regimens globally. Lepr Rev. 2012; 83: 241–244.
dc.relation	/ref/Gerzaín Rodríguez Toro, Rafael Pinto García. Mujer Joven con epistaxis, fiebre y nódulos cutáneos, agravados durante su segundo embarazo. Cuadernos de Medicina.2007;1(1).
dc.relation	/ref/Gerzaín Rodríguez, María Claudia Abaúnza, Elga Vargas, Fernando López. La lepra y el Testículo. Biomédica.2012; 32:13-22.
dc.relation	/ref/David M. Scollard. Chemotherapy of leprosy has changed (almost) everything. Lepr Rev. 2012;83:245–246.
dc.relation	/ref/Pocaterra L, Jain S, Reddy R, Muzaffrullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: An 11 year cohort study in Hyderabad, India. Am J Trop Med Hyg. 2006; 74:868-79.
dc.relation	/ref/Ministerio de Protección social. Plan estratégico de Colombia para aliviar la carga de la enfermedad y sostener las actividades de control de la lepra. 2010-2015. Bogotá: Gráficas Ducal; 2009.
dc.relation	/ref/Organización Panamericana de la Salud (OPS). Fedesalud. Ministerio de Protección social. Guía de Atención Integral de la Lepra. 2010.
dc.relation	/ref/Kaimal, S., & Thappa, D. M. Relapse in leprosy. Indian Journal of Dermatology, Venereology, and Leprology.2009; 75(2): 126.
dc.relation	/ref/Shen J, Liu M, Zhang J, Su W, Ding G. Relapse in MB leprosy patients treated with 24 months of MDT in south west China: A short report. Lepr Rev. 2006; 77:219-24.
dc.relation	/ref/Sowmya, K., & Devinder, M. Relapse in leprosy. Indian J Lepr.2009; 75:126-135.
dc.relation	/ref/Steven L. Walker, Michael F.R. Waters & Diana N.J. Lockwood. The Role of Thalidomide in the management of erythema nodosum leprosum. Lepr Rev. 2007;78:197–215.
dc.relation	/ref/Zhang, F. R., Huang, W., Chen, S. M., Sun, L. D., Liu, H., Li, Y.,... & Yu, J. P. Genome wide association study of leprosy. New England Journal of Medicine. 2009; 361(27): 2609-2618.
dc.relation	/ref/Vasudha A. Belgaumkar, Neetar R. Gokhale, Pradeep M. Mahajan, Renu Bharadwaj, Dakshayani P Pandit & Shantanu Deshpande. Lepr Rev. 2007;78: 223–230.
dc.relation	/ref/Harminder Singh, Bithika Nel, Vibek Dey, Pawan Tiwari & Naveen Dulhani. Lepr Rev. 2011; 82:17–24.
dc.relation	/ref/Mitranna Poojabylaiah, Ramesh Bhat Marne, Rajina Varikkodan, Nandakishore Bala, Sukumar Dandakeri & Jacintha Martis. Relapses in multibacillary leprosy patients after Multidrug therapy. Lepr Rev. 2008; 79: 320-324.
dc.relation	/ref/Laura c Rodrigues, Diana J.N Lockwood. Leprosy now: Epidemiology, progress, challenges, and research gaps. The Lancet Infectious Diseases.2011; 6:464-470.
dc.relation	/ref/Walker, Stephen L.; Peter Nicholls; Sushmita Dhakal; Rachel Hawksworth; Murdo MacDonald,; Kishori Mahat; et al. A Comparison of the Change in Clinical Severity Scale Score and a Retrospective Physician Assessment of Neurological Outcome in Individuals with Leprosy Associated Nerve Function Impairment after Treatment with Corticosteroids. Leprosy Review. British Leprosy Relief Association. 2012.
dc.relation	/ref/Alter, A., Alcaïs, A., Abel, L., & Schurr, E. Leprosy as a genetic model for susceptibility to common infectious diseases. Human genetics. 2008;123(3): 227-235.
dc.relation	/ref/O.A. Chichava, L. Ariza, A.R. Oliveira, A.C. Ferreira, L.F. Marques Da Silva, J.C. Barbosa, A.N. Ramos JR & J. Heukelbach. Reasons for interrupting multidrug therapy against leprosy: The patients´ point of view. Lepr Rev. 2011; 82:78–79.
dc.relation	/ref/Maria Pena, Annemieke Geluk, Jolien J. Van Der Ploeg- Van Schip, Kees L.M.C. Franken, Rahul Sharma & Richard Trauman. Cytokine responses to Mycobacterium leprae unique proteins differentiate between Mycobacterium leprae infected and naïve armadillos. Lepr Rev. 2011; 82: 422 – 431.
dc.rights	Copyright (c) 2014 NOVA Publicación en Ciencias Biomédicas	es-ES
dc.rights	http://creativecommons.org/licenses/by/4.0	es-ES
dc.source	NOVA Biomedical Sciences Journal; Vol. 12, Núm. 21 (2014); 109-114	en-US
dc.source	Nova; Vol. 12, Núm. 21 (2014); 109-114	es-ES
dc.source	NOVA Ciências Biomédicas Publicação; Vol. 12, Núm. 21 (2014); 109-114	pt-BR
dc.source	2462-9448
dc.source	1794-2470
dc.subject	bacillary index; leprosy; polychemotherapy; relapse.	en-US
dc.subject	índice bacilar; lepra; poliquimioterapia; recidiva.	es-ES
dc.title	Relapse in leprosy and type II reaction in a patient treated with multidrug therapy (MDT)	en-US
dc.title	Recidiva de lepra y reacción tipo II en paciente tratado con poliquimioterapia (PQT)	es-ES
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	studyCase	en-US
dc.type	studyCase	es-ES
dc.type	studyCase	pt-BR